Summit Therapeutics Inc.
NASDAQSummit Therapeutics exited its June 10 earnings print with an unusual split: insiders loading up on stock while short sellers simultaneously rebuilt positions at the fastest weekly pace in months, setting up a post-earnings tension between internal conviction and external skepticism. Short interest jumped 23% in a single session on June 9, lifting the total to nearly 37.3 million…
SMMT short interest surges 22.7% in one week to 4.8% of float, driven by equity research downgrades and delayed clinical data.
Snapshot as of 22 Jun 2026
Summit Therapeutics exited its June 10 earnings print with an unusual split: insiders loading up on stock while short sellers simultaneously rebuilt positions at the fastest weekly pace in months, setting up a…
Summit Therapeutics heads into its June 10 earnings report with its own executives making a conspicuous case for the stock just days before the release. On June 4, CEO Maky Zanganeh purchased 100,000 shares at $14.60 —…
Summit Therapeutics heads into its May 4 Q1 print riding a sharp reversal — up 26% in a month — while options traders quietly lean more bullish than at almost any point this year. The clearest positioning signal is in…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SMMT — free to start on ORTEX.
Sign up for free →Open SMMT on ORTEX